Alpha-conotoxins act on postsynaptic membranes, they bind to the nicotinic acetylcholine receptors (nAChR) and thus inhibit them. This toxin provokes a nearly complete and slowly reversible inhibition of both the human adult (alpha-1-beta-1-epsilon-delta (CHRNA1-CHRNB1-CHRND-CHRNE)) and human fetal (alpha-1-beta-1-gamma-delta (CHRNA1-CHRNB1-CHRNG-CHRND)) neuromuscular nAChRs (PubMed:15910004, PubMed:26074268). It also reversibly blocks the neuromuscular alpha-7/CHRNA7 nAChR, the alpha-3-beta-2 (CHRNA3-CHRNB2) nAChR, the chimeric alpha-6 or -3/beta-3 or -2 (CHRNA6/CHRNA3-CHRNB2-CHRNB3) nAChR and with a low potency the alpha-4-beta-2 (CHRNA4-CHRNB2) nAChR (PubMed:15910004). In addition, the toxin also inhibits the alpha-9-alpha-10 (CHRNA9-CHRNA10) nAChR with a high potency (IC(50)=187 nM) (PubMed:26074268). Expressed by the venom duct. The cysteine framework is VIII (C-C-C-C-C-C-C-C-C-C). Contains 5 disulfide bonds. Belongs to the conotoxin S superfamily.